Cargando…
Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care
INTRODUCTION: Since July 2021, a worldwide shortage of verteporfin (Visudyne®) occurred: an essential medicine required for photodynamic therapy (PDT). PDT with verteporfin has a broad range of indications in ophthalmology, including chronic central serous chorioretinopathy, polypoidal choroidal vas...
Autores principales: | Sirks, Marc J., van Dijk, Elon H.C., Rosenberg, Noa, Hollak, Carla E.M., Aslanis, Stamatios, Cheung, Chui Ming Gemmy, Chowers, Itay, Eandi, Chiara M., Freund, K. Bailey, Holz, Frank G., Kaiser, Peter K., Lotery, Andrew J., Ohno‐Matsui, Kyoko, Querques, Giuseppe, Subhi, Yousif, Tadayoni, Ramin, Wykoff, Charles C., Zur, Dinah, Diederen, Roselie M.H., Boon, Camiel J.F., Schlingemann, Reinier O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790583/ https://www.ncbi.nlm.nih.gov/pubmed/35388619 http://dx.doi.org/10.1111/aos.15148 |
Ejemplares similares
-
European Prevalence of Polypoidal Choroidal Vasculopathy: A Systematic Review, Meta-Analysis, and Forecasting Study
por: van Dijk, Elon H. C., et al.
Publicado: (2022) -
Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne(®)), in the CAM model
por: Debefve, E., et al.
Publicado: (2008) -
SINGLE-SESSION BILATERAL REDUCED-SETTINGS PHOTODYNAMIC THERAPY FOR BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Pauleikhoff, Laurenz J.B., et al.
Publicado: (2023) -
Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010) -
Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3
por: Feenstra, Helena M. A., et al.
Publicado: (2022)